#FORMAT=WebAnno TSV 3.2
#T_SP=webanno.custom.Referent|entity|infstat
#T_RL=webanno.custom.Coref|type|BT_webanno.custom.Referent


#Text=5 .
1-1	0-1	5	quantity	new	_	_
1-2	2-3	.	_	_	_	_

#Text=Conclusions and Perspectives
2-1	4-15	Conclusions	abstract	new	_	_
2-2	16-19	and	_	_	_	_
2-3	20-32	Perspectives	abstract	new	_	_

#Text=EGFR-TKIs are currently the standard first-line treatment of patients with advanced NSCLC with activating EGFR mutations .
3-1	33-42	EGFR-TKIs	abstract	new	coref	3-3[5_0]
3-2	43-46	are	_	_	_	_
3-3	47-56	currently	abstract[5]	giv[5]	coref	7-2[0_5]
3-4	57-60	the	abstract[5]	giv[5]	_	_
3-5	61-69	standard	abstract[5]	giv[5]	_	_
3-6	70-80	first-line	abstract[5]	giv[5]	_	_
3-7	81-90	treatment	abstract[5]	giv[5]	_	_
3-8	91-93	of	abstract[5]	giv[5]	_	_
3-9	94-102	patients	abstract[5]|person[6]	giv[5]|new[6]	coref	14-24[103_6]
3-10	103-107	with	abstract[5]|person[6]	giv[5]|new[6]	_	_
3-11	108-116	advanced	abstract[5]|person[6]|abstract[7]	giv[5]|new[6]|new[7]	coref	9-9[51_7]
3-12	117-122	NSCLC	abstract[5]|person[6]|abstract[7]	giv[5]|new[6]|new[7]	_	_
3-13	123-127	with	_	_	_	_
3-14	128-138	activating	_	_	_	_
3-15	139-143	EGFR	abstract|abstract[9]	new|new[9]	_	_
3-16	144-153	mutations	abstract[9]	new[9]	_	_
3-17	154-155	.	_	_	_	_

#Text=These targeted therapies are usually well tolerated comparative to conventional chemotherapy .
4-1	156-161	These	abstract[10]	new[10]	_	_
4-2	162-170	targeted	abstract[10]	new[10]	_	_
4-3	171-180	therapies	abstract[10]	new[10]	_	_
4-4	181-184	are	_	_	_	_
4-5	185-192	usually	_	_	_	_
4-6	193-197	well	_	_	_	_
4-7	198-207	tolerated	_	_	_	_
4-8	208-219	comparative	_	_	_	_
4-9	220-222	to	_	_	_	_
4-10	223-235	conventional	object[11]	new[11]	coref	21-8[147_11]
4-11	236-248	chemotherapy	object[11]	new[11]	_	_
4-12	249-250	.	_	_	_	_

#Text=The self-oral administration of the drug positively contributes to improving patient compliance and reducing the use of hospital resources .
5-1	251-254	The	organization[12]	new[12]	coref	6-7[0_12]
5-2	255-264	self-oral	organization[12]	new[12]	_	_
5-3	265-279	administration	organization[12]	new[12]	_	_
5-4	280-282	of	organization[12]	new[12]	_	_
5-5	283-286	the	organization[12]|substance[13]	new[12]|new[13]	coref	6-18[0_13]
5-6	287-291	drug	organization[12]|substance[13]	new[12]|new[13]	_	_
5-7	292-302	positively	_	_	_	_
5-8	303-314	contributes	_	_	_	_
5-9	315-317	to	_	_	_	_
5-10	318-327	improving	_	_	_	_
5-11	328-335	patient	person|abstract[15]	new|new[15]	coref|coref	6-24|6-24
5-12	336-346	compliance	abstract[15]	new[15]	_	_
5-13	347-350	and	_	_	_	_
5-14	351-359	reducing	_	_	_	_
5-15	360-363	the	abstract[16]	new[16]	coref	19-38[139_16]
5-16	364-367	use	abstract[16]	new[16]	_	_
5-17	368-370	of	abstract[16]	new[16]	_	_
5-18	371-379	hospital	abstract[16]|place|abstract[18]	new[16]|new|new[18]	_	_
5-19	380-389	resources	abstract[16]|abstract[18]	new[16]|new[18]	_	_
5-20	390-391	.	_	_	_	_

#Text=However , this non-invasive route of administration is also associated with unpredictable bioavailability , increased risk of drug interactions , and concerns about patient safety , surveillance , and follow-up .
6-1	392-399	However	_	_	_	_
6-2	400-401	,	_	_	_	_
6-3	402-406	this	abstract[19]	new[19]	_	_
6-4	407-419	non-invasive	abstract[19]	new[19]	_	_
6-5	420-425	route	abstract[19]	new[19]	_	_
6-6	426-428	of	abstract[19]	new[19]	_	_
6-7	429-443	administration	abstract[19]|organization	new[19]|giv	_	_
6-8	444-446	is	_	_	_	_
6-9	447-451	also	_	_	_	_
6-10	452-462	associated	_	_	_	_
6-11	463-467	with	_	_	_	_
6-12	468-481	unpredictable	abstract[21]	new[21]	_	_
6-13	482-497	bioavailability	abstract[21]	new[21]	_	_
6-14	498-499	,	_	_	_	_
6-15	500-509	increased	event[22]	new[22]	_	_
6-16	510-514	risk	event[22]	new[22]	_	_
6-17	515-517	of	event[22]	new[22]	_	_
6-18	518-522	drug	event[22]|substance|abstract[24]	new[22]|giv|new[24]	coref|coref	19-22|19-22
6-19	523-535	interactions	event[22]|abstract[24]	new[22]|new[24]	_	_
6-20	536-537	,	_	_	_	_
6-21	538-541	and	_	_	_	_
6-22	542-550	concerns	abstract[25]	new[25]	_	_
6-23	551-556	about	abstract[25]	new[25]	_	_
6-24	557-564	patient	abstract[25]|person|abstract[27]	new[25]|giv|new[27]	coref|coref	8-15|8-15
6-25	565-571	safety	abstract[25]|abstract[27]	new[25]|new[27]	_	_
6-26	572-573	,	abstract[25]	new[25]	_	_
6-27	574-586	surveillance	abstract[25]|abstract	new[25]|new	_	_
6-28	587-588	,	abstract[25]	new[25]	_	_
6-29	589-592	and	abstract[25]	new[25]	_	_
6-30	593-602	follow-up	abstract[25]|event	new[25]|new	coref	10-28[65_0]
6-31	603-604	.	_	_	_	_

#Text=Chronic EGFR-TKIs underdosage may favor the selection of resistant clones and thus disease progression , and overdosage may increase the risk of dose-related side effects .
7-1	605-612	Chronic	abstract[31]	new[31]	_	_
7-2	613-622	EGFR-TKIs	abstract|abstract[31]	giv|new[31]	coref	9-4
7-3	623-634	underdosage	abstract[31]	new[31]	_	_
7-4	635-638	may	_	_	_	_
7-5	639-644	favor	_	_	_	_
7-6	645-648	the	abstract[32]	new[32]	_	_
7-7	649-658	selection	abstract[32]	new[32]	_	_
7-8	659-661	of	abstract[32]	new[32]	_	_
7-9	662-671	resistant	abstract[32]|abstract[33]	new[32]|new[33]	_	_
7-10	672-678	clones	abstract[32]|abstract[33]	new[32]|new[33]	_	_
7-11	679-682	and	abstract[32]	new[32]	_	_
7-12	683-687	thus	abstract[32]|abstract[35]	new[32]|new[35]	_	_
7-13	688-695	disease	abstract[32]|abstract|abstract[35]	new[32]|new|new[35]	coref	9-20[54_0]
7-14	696-707	progression	abstract[32]|abstract[35]	new[32]|new[35]	_	_
7-15	708-709	,	_	_	_	_
7-16	710-713	and	_	_	_	_
7-17	714-724	overdosage	abstract	new	_	_
7-18	725-728	may	_	_	_	_
7-19	729-737	increase	_	_	_	_
7-20	738-741	the	abstract[37]	new[37]	_	_
7-21	742-746	risk	abstract[37]	new[37]	_	_
7-22	747-749	of	abstract[37]	new[37]	_	_
7-23	750-762	dose-related	abstract[37]|abstract[38]	new[37]|new[38]	coref	8-8[41_38]
7-24	763-767	side	abstract[37]|abstract[38]	new[37]|new[38]	_	_
7-25	768-775	effects	abstract[37]|abstract[38]	new[37]|new[38]	_	_
7-26	776-777	.	_	_	_	_

#Text=Self-administration also means that the severity of side effects can be considerably impacted by patient behavior ( e. g. , dietary habits , self-medicating , smoker status ) .
8-1	778-797	Self-administration	abstract	new	_	_
8-2	798-802	also	_	_	_	_
8-3	803-808	means	_	_	_	_
8-4	809-813	that	_	_	_	_
8-5	814-817	the	abstract[40]	new[40]	_	_
8-6	818-826	severity	abstract[40]	new[40]	_	_
8-7	827-829	of	abstract[40]	new[40]	_	_
8-8	830-834	side	abstract[40]|abstract[41]	new[40]|giv[41]	coref	25-32[198_41]
8-9	835-842	effects	abstract[40]|abstract[41]	new[40]|giv[41]	_	_
8-10	843-846	can	_	_	_	_
8-11	847-849	be	_	_	_	_
8-12	850-862	considerably	_	_	_	_
8-13	863-871	impacted	_	_	_	_
8-14	872-874	by	_	_	_	_
8-15	875-882	patient	person|abstract[43]	giv|new[43]	appos|coref|appos|coref	8-21[45_43]|12-14|8-21[45_43]|12-14
8-16	883-891	behavior	abstract[43]	new[43]	_	_
8-17	892-893	(	_	_	_	_
8-18	894-896	e.	_	_	_	_
8-19	897-899	g.	_	_	_	_
8-20	900-901	,	_	_	_	_
8-21	902-909	dietary	abstract|abstract[45]	new|giv[45]	appos|appos	8-24[0_45]|8-24[0_45]
8-22	910-916	habits	abstract[45]	giv[45]	_	_
8-23	917-918	,	_	_	_	_
8-24	919-934	self-medicating	abstract	giv	appos	8-26[48_0]
8-25	935-936	,	_	_	_	_
8-26	937-943	smoker	person|abstract[48]	new|giv[48]	_	_
8-27	944-950	status	abstract[48]	giv[48]	_	_
8-28	951-952	)	_	_	_	_
8-29	953-954	.	_	_	_	_

#Text=To date , EGFR-TKIs can be administered in advanced NSCLC for a long period of time , usually until the disease progresses or unacceptable toxicity occurs .
9-1	955-957	To	_	_	_	_
9-2	958-962	date	time	new	_	_
9-3	963-964	,	_	_	_	_
9-4	965-974	EGFR-TKIs	abstract	giv	_	_
9-5	975-978	can	_	_	_	_
9-6	979-981	be	_	_	_	_
9-7	982-994	administered	_	_	_	_
9-8	995-997	in	_	_	_	_
9-9	998-1006	advanced	abstract[51]	giv[51]	coref	28-24[0_51]
9-10	1007-1012	NSCLC	abstract[51]	giv[51]	_	_
9-11	1013-1016	for	_	_	_	_
9-12	1017-1018	a	time[52]	new[52]	_	_
9-13	1019-1023	long	time[52]	new[52]	_	_
9-14	1024-1030	period	time[52]	new[52]	_	_
9-15	1031-1033	of	time[52]	new[52]	_	_
9-16	1034-1038	time	time[52]|time	new[52]|new	_	_
9-17	1039-1040	,	_	_	_	_
9-18	1041-1048	usually	_	_	_	_
9-19	1049-1054	until	_	_	_	_
9-20	1055-1058	the	abstract[54]	giv[54]	coref	14-4[0_54]
9-21	1059-1066	disease	abstract[54]	giv[54]	_	_
9-22	1067-1077	progresses	_	_	_	_
9-23	1078-1080	or	_	_	_	_
9-24	1081-1093	unacceptable	abstract[55]	new[55]	coref	10-29[0_55]
9-25	1094-1102	toxicity	abstract[55]	new[55]	_	_
9-26	1103-1109	occurs	_	_	_	_
9-27	1110-1111	.	_	_	_	_

#Text=As early intervention with supportive care strategies can minimize the intensity of adverse reactions or allow for appropriate dose adjustments without the need to discontinue treatment , acute toxicity follow-up and side effect management is of major interest .
10-1	1112-1114	As	_	_	_	_
10-2	1115-1120	early	_	_	_	_
10-3	1121-1133	intervention	_	_	_	_
10-4	1134-1138	with	_	_	_	_
10-5	1139-1149	supportive	abstract[57]	new[57]	coref	12-4[79_57]
10-6	1150-1154	care	abstract|abstract[57]	new|new[57]	coref	12-27[87_0]
10-7	1155-1165	strategies	abstract[57]	new[57]	_	_
10-8	1166-1169	can	_	_	_	_
10-9	1170-1178	minimize	_	_	_	_
10-10	1179-1182	the	abstract[58]	new[58]	_	_
10-11	1183-1192	intensity	abstract[58]	new[58]	_	_
10-12	1193-1195	of	abstract[58]	new[58]	_	_
10-13	1196-1203	adverse	abstract[58]|abstract[59]	new[58]|new[59]	_	_
10-14	1204-1213	reactions	abstract[58]|abstract[59]	new[58]|new[59]	_	_
10-15	1214-1216	or	_	_	_	_
10-16	1217-1222	allow	_	_	_	_
10-17	1223-1226	for	_	_	_	_
10-18	1227-1238	appropriate	event[61]	new[61]	_	_
10-19	1239-1243	dose	quantity|event[61]	new|new[61]	coref	22-20
10-20	1244-1255	adjustments	event[61]	new[61]	_	_
10-21	1256-1263	without	_	_	_	_
10-22	1264-1267	the	abstract[62]	new[62]	coref	17-18[117_62]
10-23	1268-1272	need	abstract[62]	new[62]	_	_
10-24	1273-1275	to	_	_	_	_
10-25	1276-1287	discontinue	_	_	_	_
10-26	1288-1297	treatment	event	new	coref	11-38
10-27	1298-1299	,	_	_	_	_
10-28	1300-1305	acute	event[65]	giv[65]	coref	20-4[143_65]
10-29	1306-1314	toxicity	abstract|event[65]	giv|giv[65]	coref	15-8
10-30	1315-1324	follow-up	event[65]	giv[65]	_	_
10-31	1325-1328	and	_	_	_	_
10-32	1329-1333	side	abstract[67]	new[67]	_	_
10-33	1334-1340	effect	abstract|abstract[67]	new|new[67]	_	_
10-34	1341-1351	management	abstract[67]	new[67]	_	_
10-35	1352-1354	is	_	_	_	_
10-36	1355-1357	of	_	_	_	_
10-37	1358-1363	major	abstract[68]	new[68]	_	_
10-38	1364-1372	interest	abstract[68]	new[68]	_	_
10-39	1373-1374	.	_	_	_	_

#Text=Therefore , medical oncologists should not only understand the AEs associated with these drugs , but also develop the necessary skills to detect and treat them to reduce morbidity and mortality as well as premature discontinuation of treatment .
11-1	1375-1384	Therefore	_	_	_	_
11-2	1385-1386	,	_	_	_	_
11-3	1387-1394	medical	person[69]	new[69]	coref	19-3[126_69]
11-4	1395-1406	oncologists	person[69]	new[69]	_	_
11-5	1407-1413	should	_	_	_	_
11-6	1414-1417	not	_	_	_	_
11-7	1418-1422	only	_	_	_	_
11-8	1423-1433	understand	_	_	_	_
11-9	1434-1437	the	abstract[70]	new[70]	coref	17-16[0_70]
11-10	1438-1441	AEs	abstract[70]	new[70]	_	_
11-11	1442-1452	associated	_	_	_	_
11-12	1453-1457	with	_	_	_	_
11-13	1458-1463	these	substance[71]	new[71]	_	_
11-14	1464-1469	drugs	substance[71]	new[71]	_	_
11-15	1470-1471	,	_	_	_	_
11-16	1472-1475	but	_	_	_	_
11-17	1476-1480	also	_	_	_	_
11-18	1481-1488	develop	_	_	_	_
11-19	1489-1492	the	abstract[72]	new[72]	ana	11-26[0_72]
11-20	1493-1502	necessary	abstract[72]	new[72]	_	_
11-21	1503-1509	skills	abstract[72]	new[72]	_	_
11-22	1510-1512	to	_	_	_	_
11-23	1513-1519	detect	_	_	_	_
11-24	1520-1523	and	_	_	_	_
11-25	1524-1529	treat	_	_	_	_
11-26	1530-1534	them	abstract	giv	_	_
11-27	1535-1537	to	_	_	_	_
11-28	1538-1544	reduce	_	_	_	_
11-29	1545-1554	morbidity	abstract	new	_	_
11-30	1555-1558	and	_	_	_	_
11-31	1559-1568	mortality	event	new	_	_
11-32	1569-1571	as	_	_	_	_
11-33	1572-1576	well	_	_	_	_
11-34	1577-1579	as	_	_	_	_
11-35	1580-1589	premature	event[76]	new[76]	coref	24-27[0_76]
11-36	1590-1605	discontinuation	event[76]	new[76]	_	_
11-37	1606-1608	of	event[76]	new[76]	_	_
11-38	1609-1618	treatment	event[76]|event	new[76]|giv	coref	12-23
11-39	1619-1620	.	_	_	_	_

#Text=Patient education on these strategies is also of major importance and can improve patient tolerance , quality of life , and overall treatment outcome by initiating supportive care soon after symptoms occur .
12-1	1621-1628	Patient	abstract[78]	new[78]	coref	19-11[129_78]
12-2	1629-1638	education	abstract[78]	new[78]	_	_
12-3	1639-1641	on	abstract[78]	new[78]	_	_
12-4	1642-1647	these	abstract[78]|abstract[79]	new[78]|giv[79]	coref	18-19[125_79]
12-5	1648-1658	strategies	abstract[78]|abstract[79]	new[78]|giv[79]	_	_
12-6	1659-1661	is	_	_	_	_
12-7	1662-1666	also	_	_	_	_
12-8	1667-1669	of	_	_	_	_
12-9	1670-1675	major	abstract[80]	new[80]	coref	20-1[141_80]
12-10	1676-1686	importance	abstract[80]	new[80]	_	_
12-11	1687-1690	and	_	_	_	_
12-12	1691-1694	can	_	_	_	_
12-13	1695-1702	improve	_	_	_	_
12-14	1703-1710	patient	person|abstract[82]	giv|new[82]	coref|coref	19-11|19-11
12-15	1711-1720	tolerance	abstract[82]	new[82]	_	_
12-16	1721-1722	,	_	_	_	_
12-17	1723-1730	quality	abstract[83]	new[83]	_	_
12-18	1731-1733	of	abstract[83]	new[83]	_	_
12-19	1734-1738	life	abstract[83]|abstract	new[83]|new	coref	21-27
12-20	1739-1740	,	_	_	_	_
12-21	1741-1744	and	_	_	_	_
12-22	1745-1752	overall	abstract[86]	new[86]	_	_
12-23	1753-1762	treatment	event|abstract[86]	giv|new[86]	coref	14-17
12-24	1763-1770	outcome	abstract[86]	new[86]	_	_
12-25	1771-1773	by	_	_	_	_
12-26	1774-1784	initiating	_	_	_	_
12-27	1785-1795	supportive	abstract[87]	giv[87]	coref	28-18[226_87]
12-28	1796-1800	care	abstract[87]	giv[87]	_	_
12-29	1801-1805	soon	_	_	_	_
12-30	1806-1811	after	_	_	_	_
12-31	1812-1820	symptoms	abstract	new	_	_
12-32	1821-1826	occur	_	_	_	_
12-33	1827-1828	.	_	_	_	_

#Text=Within this guidance and preventive strategy , the pharmacist can play a major role .
13-1	1829-1835	Within	_	_	_	_
13-2	1836-1840	this	abstract[89]	new[89]	_	_
13-3	1841-1849	guidance	abstract[89]	new[89]	_	_
13-4	1850-1853	and	_	_	_	_
13-5	1854-1864	preventive	abstract[90]	new[90]	_	_
13-6	1865-1873	strategy	abstract[90]	new[90]	_	_
13-7	1874-1875	,	_	_	_	_
13-8	1876-1879	the	person[91]	new[91]	_	_
13-9	1880-1890	pharmacist	person[91]	new[91]	_	_
13-10	1891-1894	can	_	_	_	_
13-11	1895-1899	play	_	_	_	_
13-12	1900-1901	a	abstract[92]	new[92]	_	_
13-13	1902-1907	major	abstract[92]	new[92]	_	_
13-14	1908-1912	role	abstract[92]	new[92]	_	_
13-15	1913-1914	.	_	_	_	_

#Text=Good knowledge of disease monitoring , response milestones , and the risks versus benefits of the treatment options allows pharmacists to better advise patients or counsel patients more effectively .
14-1	1915-1919	Good	abstract[93]	new[93]	_	_
14-2	1920-1929	knowledge	abstract[93]	new[93]	_	_
14-3	1930-1932	of	abstract[93]	new[93]	_	_
14-4	1933-1940	disease	abstract[93]|abstract|event[95]	new[93]|giv|new[95]	coref|coref|coref|coref	19-23[0_95]|27-25|19-23[0_95]|27-25
14-5	1941-1951	monitoring	abstract[93]|event[95]	new[93]|new[95]	_	_
14-6	1952-1953	,	abstract[93]	new[93]	_	_
14-7	1954-1962	response	abstract[93]|abstract|event[97]	new[93]|new|new[97]	coref|coref	27-25[215_0]|27-25[215_0]
14-8	1963-1973	milestones	abstract[93]|event[97]	new[93]|new[97]	_	_
14-9	1974-1975	,	abstract[93]	new[93]	_	_
14-10	1976-1979	and	abstract[93]	new[93]	_	_
14-11	1980-1983	the	abstract[93]|abstract[98]	new[93]|new[98]	coref	15-8[108_98]
14-12	1984-1989	risks	abstract[93]|abstract[98]	new[93]|new[98]	_	_
14-13	1990-1996	versus	abstract[93]|abstract[98]	new[93]|new[98]	_	_
14-14	1997-2005	benefits	abstract[93]|abstract[98]|abstract[99]	new[93]|new[98]|new[99]	_	_
14-15	2006-2008	of	abstract[93]|abstract[98]|abstract[99]	new[93]|new[98]|new[99]	_	_
14-16	2009-2012	the	abstract[93]|abstract[98]|abstract[99]|abstract[101]	new[93]|new[98]|new[99]|new[101]	_	_
14-17	2013-2022	treatment	abstract[93]|abstract[98]|abstract[99]|abstract|abstract[101]	new[93]|new[98]|new[99]|giv|new[101]	_	_
14-18	2023-2030	options	abstract[93]|abstract[98]|abstract[99]|abstract[101]	new[93]|new[98]|new[99]|new[101]	_	_
14-19	2031-2037	allows	_	_	_	_
14-20	2038-2049	pharmacists	person	new	coref	17-5
14-21	2050-2052	to	_	_	_	_
14-22	2053-2059	better	_	_	_	_
14-23	2060-2066	advise	_	_	_	_
14-24	2067-2075	patients	person[103]	giv[103]	coref	17-1[0_103]
14-25	2076-2078	or	person[103]	giv[103]	_	_
14-26	2079-2086	counsel	person[103]	giv[103]	_	_
14-27	2087-2095	patients	person[103]	giv[103]	_	_
14-28	2096-2100	more	_	_	_	_
14-29	2101-2112	effectively	_	_	_	_
14-30	2113-2114	.	_	_	_	_

#Text=Nurses and prescribers are qualified to monitor toxicity risks as closely as possible .
15-1	2115-2121	Nurses	person|person[105]	new|new[105]	coref|coref|coref|coref	18-14|18-14[123_105]|18-14|18-14[123_105]
15-2	2122-2125	and	person[105]	new[105]	_	_
15-3	2126-2137	prescribers	person[105]|person	new[105]|new	ana	16-3
15-4	2138-2141	are	_	_	_	_
15-5	2142-2151	qualified	_	_	_	_
15-6	2152-2154	to	_	_	_	_
15-7	2155-2162	monitor	_	_	_	_
15-8	2163-2171	toxicity	abstract|abstract[108]	giv|giv[108]	_	_
15-9	2172-2177	risks	abstract[108]	giv[108]	_	_
15-10	2178-2180	as	_	_	_	_
15-11	2181-2188	closely	_	_	_	_
15-12	2189-2191	as	_	_	_	_
15-13	2192-2200	possible	_	_	_	_
15-14	2201-2202	.	_	_	_	_

#Text=Unfortunately , they do not necessarily do so at regular intervals .
16-1	2203-2216	Unfortunately	_	_	_	_
16-2	2217-2218	,	_	_	_	_
16-3	2219-2223	they	person	giv	coref	17-25
16-4	2224-2226	do	_	_	_	_
16-5	2227-2230	not	_	_	_	_
16-6	2231-2242	necessarily	_	_	_	_
16-7	2243-2245	do	_	_	_	_
16-8	2246-2248	so	_	_	_	_
16-9	2249-2251	at	_	_	_	_
16-10	2252-2259	regular	abstract[110]	new[110]	_	_
16-11	2260-2269	intervals	abstract[110]	new[110]	_	_
16-12	2270-2271	.	_	_	_	_

#Text=Patients can connect with pharmacists who can provide them additional information or complementary recommendations on AEs without the need for patients to rapidly contact prescribers .
17-1	2272-2280	Patients	person	giv	coref	17-21
17-2	2281-2284	can	_	_	_	_
17-3	2285-2292	connect	_	_	_	_
17-4	2293-2297	with	_	_	_	_
17-5	2298-2309	pharmacists	person	giv	ana	17-9
17-6	2310-2313	who	_	_	_	_
17-7	2314-2317	can	_	_	_	_
17-8	2318-2325	provide	_	_	_	_
17-9	2326-2330	them	person	giv	coref	18-9
17-10	2331-2341	additional	abstract[114]	new[114]	_	_
17-11	2342-2353	information	abstract[114]	new[114]	_	_
17-12	2354-2356	or	_	_	_	_
17-13	2357-2370	complementary	abstract[115]	new[115]	_	_
17-14	2371-2386	recommendations	abstract[115]	new[115]	_	_
17-15	2387-2389	on	abstract[115]	new[115]	_	_
17-16	2390-2393	AEs	abstract[115]|abstract	new[115]|giv	coref	18-2[120_0]
17-17	2394-2401	without	_	_	_	_
17-18	2402-2405	the	abstract[117]	giv[117]	_	_
17-19	2406-2410	need	abstract[117]	giv[117]	_	_
17-20	2411-2414	for	abstract[117]	giv[117]	_	_
17-21	2415-2423	patients	abstract[117]|person	giv[117]|giv	coref	21-6
17-22	2424-2426	to	_	_	_	_
17-23	2427-2434	rapidly	_	_	_	_
17-24	2435-2442	contact	_	_	_	_
17-25	2443-2454	prescribers	person	giv	coref	18-16
17-26	2455-2456	.	_	_	_	_

#Text=When more complex or serious AEs appear , pharmacists who work closely with nurses and prescribers can propose the most appropriate therapeutic strategies .
18-1	2457-2461	When	_	_	_	_
18-2	2462-2466	more	abstract[120]	giv[120]	coref	19-8[0_120]
18-3	2467-2474	complex	abstract[120]	giv[120]	_	_
18-4	2475-2477	or	abstract[120]	giv[120]	_	_
18-5	2478-2485	serious	abstract[120]	giv[120]	_	_
18-6	2486-2489	AEs	abstract[120]	giv[120]	_	_
18-7	2490-2496	appear	_	_	_	_
18-8	2497-2498	,	_	_	_	_
18-9	2499-2510	pharmacists	person	giv	_	_
18-10	2511-2514	who	_	_	_	_
18-11	2515-2519	work	_	_	_	_
18-12	2520-2527	closely	_	_	_	_
18-13	2528-2532	with	_	_	_	_
18-14	2533-2539	nurses	person|person[123]	giv|giv[123]	coref|coref	28-11|28-11
18-15	2540-2543	and	person[123]	giv[123]	_	_
18-16	2544-2555	prescribers	person[123]|person	giv[123]|giv	_	_
18-17	2556-2559	can	_	_	_	_
18-18	2560-2567	propose	_	_	_	_
18-19	2568-2571	the	abstract[125]	giv[125]	_	_
18-20	2572-2576	most	abstract[125]	giv[125]	_	_
18-21	2577-2588	appropriate	abstract[125]	giv[125]	_	_
18-22	2589-2600	therapeutic	abstract[125]	giv[125]	_	_
18-23	2601-2611	strategies	abstract[125]	giv[125]	_	_
18-24	2612-2613	.	_	_	_	_

#Text=Finally , medical oncologists able to understand AEs along with patient education and collaboration between different medical professional groups for therapeutic drug monitoring systems are needed , but further research on the aforementioned methods of relief for continued TKI use should be also performed in the future .
19-1	2614-2621	Finally	_	_	_	_
19-2	2622-2623	,	_	_	_	_
19-3	2624-2631	medical	person[126]	giv[126]	coref	28-4[222_126]
19-4	2632-2643	oncologists	person[126]	giv[126]	_	_
19-5	2644-2648	able	_	_	_	_
19-6	2649-2651	to	_	_	_	_
19-7	2652-2662	understand	_	_	_	_
19-8	2663-2666	AEs	abstract	giv	coref	22-29[169_0]
19-9	2667-2672	along	_	_	_	_
19-10	2673-2677	with	_	_	_	_
19-11	2678-2685	patient	person|abstract[129]	giv|giv[129]	coref|coref|coref|coref	20-5|27-9[207_129]|20-5|27-9[207_129]
19-12	2686-2695	education	abstract[129]	giv[129]	_	_
19-13	2696-2699	and	_	_	_	_
19-14	2700-2713	collaboration	abstract[130]	new[130]	_	_
19-15	2714-2721	between	abstract[130]	new[130]	_	_
19-16	2722-2731	different	abstract[130]|person[131]	new[130]|new[131]	_	_
19-17	2732-2739	medical	abstract[130]|person[131]	new[130]|new[131]	_	_
19-18	2740-2752	professional	abstract[130]|person[131]	new[130]|new[131]	_	_
19-19	2753-2759	groups	abstract[130]|person[131]	new[130]|new[131]	_	_
19-20	2760-2763	for	abstract[130]|person[131]	new[130]|new[131]	_	_
19-21	2764-2775	therapeutic	abstract[130]|person[131]|abstract[134]	new[130]|new[131]|new[134]	_	_
19-22	2776-2780	drug	abstract[130]|person[131]|substance|abstract[134]	new[130]|new[131]|giv|new[134]	coref	27-9
19-23	2781-2791	monitoring	abstract[130]|person[131]|event|abstract[134]	new[130]|new[131]|giv|new[134]	_	_
19-24	2792-2799	systems	abstract[130]|person[131]|abstract[134]	new[130]|new[131]|new[134]	_	_
19-25	2800-2803	are	_	_	_	_
19-26	2804-2810	needed	_	_	_	_
19-27	2811-2812	,	_	_	_	_
19-28	2813-2816	but	_	_	_	_
19-29	2817-2824	further	abstract[135]	new[135]	_	_
19-30	2825-2833	research	abstract[135]	new[135]	_	_
19-31	2834-2836	on	abstract[135]	new[135]	_	_
19-32	2837-2840	the	abstract[135]|abstract[136]	new[135]|new[136]	_	_
19-33	2841-2855	aforementioned	abstract[135]|abstract[136]	new[135]|new[136]	_	_
19-34	2856-2863	methods	abstract[135]|abstract[136]	new[135]|new[136]	_	_
19-35	2864-2866	of	abstract[135]|abstract[136]	new[135]|new[136]	_	_
19-36	2867-2873	relief	abstract[135]|abstract[136]|abstract[137]	new[135]|new[136]|new[137]	_	_
19-37	2874-2877	for	abstract[135]|abstract[136]|abstract[137]	new[135]|new[136]|new[137]	_	_
19-38	2878-2887	continued	abstract[135]|abstract[136]|abstract[137]|abstract[139]	new[135]|new[136]|new[137]|giv[139]	_	_
19-39	2888-2891	TKI	abstract[135]|abstract[136]|abstract[137]|place|abstract[139]	new[135]|new[136]|new[137]|new|giv[139]	_	_
19-40	2892-2895	use	abstract[135]|abstract[136]|abstract[137]|abstract[139]	new[135]|new[136]|new[137]|giv[139]	_	_
19-41	2896-2902	should	_	_	_	_
19-42	2903-2905	be	_	_	_	_
19-43	2906-2910	also	_	_	_	_
19-44	2911-2920	performed	_	_	_	_
19-45	2921-2923	in	_	_	_	_
19-46	2924-2927	the	time[140]	new[140]	_	_
19-47	2928-2934	future	time[140]	new[140]	_	_
19-48	2935-2936	.	_	_	_	_

#Text=The importance of proactive patient follow-up must be emphasized rather than relying on self-reporting between clinical visits .
20-1	2937-2940	The	abstract[141]	giv[141]	_	_
20-2	2941-2951	importance	abstract[141]	giv[141]	_	_
20-3	2952-2954	of	abstract[141]	giv[141]	_	_
20-4	2955-2964	proactive	abstract[141]|event[143]	giv[141]|giv[143]	coref	22-14[0_143]
20-5	2965-2972	patient	abstract[141]|person|event[143]	giv[141]|giv|giv[143]	coref	27-6
20-6	2973-2982	follow-up	abstract[141]|event[143]	giv[141]|giv[143]	_	_
20-7	2983-2987	must	_	_	_	_
20-8	2988-2990	be	_	_	_	_
20-9	2991-3001	emphasized	_	_	_	_
20-10	3002-3008	rather	_	_	_	_
20-11	3009-3013	than	_	_	_	_
20-12	3014-3021	relying	_	_	_	_
20-13	3022-3024	on	_	_	_	_
20-14	3025-3039	self-reporting	_	_	_	_
20-15	3040-3047	between	_	_	_	_
20-16	3048-3056	clinical	event[144]	new[144]	coref	21-29[157_144]
20-17	3057-3063	visits	event[144]	new[144]	_	_
20-18	3064-3065	.	_	_	_	_

#Text=A randomized trial showed that patients receiving chemotherapy for advanced cancer , web-based symptom reporting with automated clinician e-mail alerts resulted in better health-related quality of life , fewer emergency room visits , fewer hospitalizations , and superior quality-adjusted survival .
21-1	3066-3067	A	abstract[145]	new[145]	_	_
21-2	3068-3078	randomized	abstract[145]	new[145]	_	_
21-3	3079-3084	trial	abstract[145]	new[145]	_	_
21-4	3085-3091	showed	_	_	_	_
21-5	3092-3096	that	_	_	_	_
21-6	3097-3105	patients	person	giv	coref	22-31[170_0]
21-7	3106-3115	receiving	_	_	_	_
21-8	3116-3128	chemotherapy	object[147]	giv[147]	_	_
21-9	3129-3132	for	object[147]	giv[147]	_	_
21-10	3133-3141	advanced	object[147]|abstract[148]	giv[147]|new[148]	_	_
21-11	3142-3148	cancer	object[147]|abstract[148]	giv[147]|new[148]	_	_
21-12	3149-3150	,	object[147]	giv[147]	_	_
21-13	3151-3160	web-based	object[147]|abstract[149]	giv[147]|new[149]	_	_
21-14	3161-3168	symptom	object[147]|abstract[149]	giv[147]|new[149]	_	_
21-15	3169-3178	reporting	_	_	_	_
21-16	3179-3183	with	_	_	_	_
21-17	3184-3193	automated	abstract[152]	new[152]	_	_
21-18	3194-3203	clinician	person|abstract[152]	new|new[152]	coref	27-3[202_0]
21-19	3204-3210	e-mail	abstract|abstract[152]	new|new[152]	_	_
21-20	3211-3217	alerts	abstract[152]	new[152]	_	_
21-21	3218-3226	resulted	_	_	_	_
21-22	3227-3229	in	_	_	_	_
21-23	3230-3236	better	abstract[153]	new[153]	_	_
21-24	3237-3251	health-related	abstract[153]	new[153]	_	_
21-25	3252-3259	quality	abstract[153]	new[153]	_	_
21-26	3260-3262	of	abstract[153]	new[153]	_	_
21-27	3263-3267	life	abstract[153]|abstract	new[153]|giv	_	_
21-28	3268-3269	,	abstract[153]	new[153]	_	_
21-29	3270-3275	fewer	abstract[153]|event[157]	new[153]|giv[157]	coref	24-15[184_157]
21-30	3276-3285	emergency	abstract[153]|abstract|event[157]	new[153]|new|giv[157]	coref	24-12
21-31	3286-3290	room	abstract[153]|place|event[157]	new[153]|new|giv[157]	coref	24-11[182_0]
21-32	3291-3297	visits	abstract[153]|event[157]	new[153]|giv[157]	_	_
21-33	3298-3299	,	abstract[153]	new[153]	_	_
21-34	3300-3305	fewer	abstract[153]|event[158]	new[153]|new[158]	_	_
21-35	3306-3322	hospitalizations	abstract[153]|event[158]	new[153]|new[158]	_	_
21-36	3323-3324	,	abstract[153]	new[153]	_	_
21-37	3325-3328	and	abstract[153]	new[153]	_	_
21-38	3329-3337	superior	abstract[153]|event[159]	new[153]|new[159]	coref	26-7[200_159]
21-39	3338-3354	quality-adjusted	abstract[153]|event[159]	new[153]|new[159]	_	_
21-40	3355-3363	survival	abstract[153]|event[159]	new[153]|new[159]	_	_
21-41	3364-3365	.	_	_	_	_

#Text=Recently , Cheema et al. assessed the impact of an interprofessional , proactive follow-up algorithm on the incidence of dose interruptions , reductions , and the severity of AEs in patients on afatinib .
22-1	3366-3374	Recently	_	_	_	_
22-2	3375-3376	,	_	_	_	_
22-3	3377-3383	Cheema	person	new	_	_
22-4	3384-3386	et	_	_	_	_
22-5	3387-3390	al.	_	_	_	_
22-6	3391-3399	assessed	_	_	_	_
22-7	3400-3403	the	abstract[161]	new[161]	_	_
22-8	3404-3410	impact	abstract[161]	new[161]	_	_
22-9	3411-3413	of	abstract[161]	new[161]	_	_
22-10	3414-3416	an	abstract[161]|abstract[163]	new[161]|new[163]	coref	24-1[179_163]
22-11	3417-3434	interprofessional	abstract[161]|abstract[163]	new[161]|new[163]	_	_
22-12	3435-3436	,	abstract[161]|abstract[163]	new[161]|new[163]	_	_
22-13	3437-3446	proactive	abstract[161]|abstract[163]	new[161]|new[163]	_	_
22-14	3447-3456	follow-up	abstract[161]|event|abstract[163]	new[161]|giv|new[163]	coref	23-24[177_0]
22-15	3457-3466	algorithm	abstract[161]|abstract[163]	new[161]|new[163]	_	_
22-16	3467-3469	on	abstract[161]	new[161]	_	_
22-17	3470-3473	the	abstract[161]|abstract[164]	new[161]|new[164]	_	_
22-18	3474-3483	incidence	abstract[161]|abstract[164]	new[161]|new[164]	_	_
22-19	3484-3486	of	abstract[161]|abstract[164]	new[161]|new[164]	_	_
22-20	3487-3491	dose	abstract[161]|abstract[164]|quantity|abstract[166]	new[161]|new[164]|giv|new[166]	_	_
22-21	3492-3505	interruptions	abstract[161]|abstract[164]|abstract[166]	new[161]|new[164]|new[166]	_	_
22-22	3506-3507	,	abstract[161]|abstract[164]	new[161]|new[164]	_	_
22-23	3508-3518	reductions	abstract[161]|abstract[164]|event	new[161]|new[164]|new	_	_
22-24	3519-3520	,	_	_	_	_
22-25	3521-3524	and	_	_	_	_
22-26	3525-3528	the	abstract[168]	new[168]	_	_
22-27	3529-3537	severity	abstract[168]	new[168]	_	_
22-28	3538-3540	of	abstract[168]	new[168]	_	_
22-29	3541-3544	AEs	abstract[168]|abstract[169]	new[168]|giv[169]	coref	23-8[174_169]
22-30	3545-3547	in	abstract[168]|abstract[169]	new[168]|giv[169]	_	_
22-31	3548-3556	patients	abstract[168]|abstract[169]|person[170]	new[168]|giv[169]|giv[170]	coref	25-7[0_170]
22-32	3557-3559	on	abstract[168]|abstract[169]|person[170]	new[168]|giv[169]|giv[170]	_	_
22-33	3560-3568	afatinib	abstract[168]|abstract[169]|person[170]|substance	new[168]|giv[169]|giv[170]|new	_	_
22-34	3569-3570	.	_	_	_	_

#Text=The authors reported that over half of first AEs and one third of all grade 1-2 and grade ≥3 AEs were detected through proactive follow-up .
23-1	3571-3574	The	person[172]	new[172]	_	_
23-2	3575-3582	authors	person[172]	new[172]	_	_
23-3	3583-3591	reported	_	_	_	_
23-4	3592-3596	that	_	_	_	_
23-5	3597-3601	over	_	_	_	_
23-6	3602-3606	half	quantity[173]	new[173]	_	_
23-7	3607-3609	of	quantity[173]	new[173]	_	_
23-8	3610-3615	first	quantity[173]|abstract[174]	new[173]|giv[174]	coref	23-19[176_174]
23-9	3616-3619	AEs	quantity[173]|abstract[174]	new[173]|giv[174]	_	_
23-10	3620-3623	and	_	_	_	_
23-11	3624-3627	one	_	_	_	_
23-12	3628-3633	third	_	_	_	_
23-13	3634-3636	of	_	_	_	_
23-14	3637-3640	all	abstract[175]	new[175]	_	_
23-15	3641-3646	grade	abstract[175]	new[175]	_	_
23-16	3647-3650	1-2	abstract[175]	new[175]	_	_
23-17	3651-3654	and	abstract[175]	new[175]	_	_
23-18	3655-3660	grade	abstract[175]	new[175]	_	_
23-19	3661-3663	≥3	abstract[176]	giv[176]	coref	24-24[186_176]
23-20	3664-3667	AEs	abstract[176]	giv[176]	_	_
23-21	3668-3672	were	_	_	_	_
23-22	3673-3681	detected	_	_	_	_
23-23	3682-3689	through	_	_	_	_
23-24	3690-3699	proactive	event[177]	giv[177]	coref	25-19[194_177]
23-25	3700-3709	follow-up	event[177]	giv[177]	_	_
23-26	3710-3711	.	_	_	_	_

#Text=This multi-disciplinary AE algorithm resulted in a low rate of costly emergency room or urgent clinic visits and a reduced incidence of severe drug-related AEs and discontinuation therapy .
24-1	3712-3716	This	abstract[179]	giv[179]	_	_
24-2	3717-3735	multi-disciplinary	abstract[179]	giv[179]	_	_
24-3	3736-3738	AE	abstract|abstract[179]	new|giv[179]	_	_
24-4	3739-3748	algorithm	abstract[179]	giv[179]	_	_
24-5	3749-3757	resulted	_	_	_	_
24-6	3758-3760	in	_	_	_	_
24-7	3761-3762	a	quantity[180]	new[180]	_	_
24-8	3763-3766	low	quantity[180]	new[180]	_	_
24-9	3767-3771	rate	quantity[180]	new[180]	_	_
24-10	3772-3774	of	quantity[180]	new[180]	_	_
24-11	3775-3781	costly	quantity[180]|place[182]	new[180]|giv[182]	_	_
24-12	3782-3791	emergency	quantity[180]|abstract|place[182]	new[180]|giv|giv[182]	_	_
24-13	3792-3796	room	quantity[180]|place[182]	new[180]|giv[182]	_	_
24-14	3797-3799	or	quantity[180]	new[180]	_	_
24-15	3800-3806	urgent	quantity[180]|event[184]	new[180]|giv[184]	_	_
24-16	3807-3813	clinic	quantity[180]|place|event[184]	new[180]|new|giv[184]	_	_
24-17	3814-3820	visits	quantity[180]|event[184]	new[180]|giv[184]	_	_
24-18	3821-3824	and	quantity[180]	new[180]	_	_
24-19	3825-3826	a	quantity[180]|abstract[185]	new[180]|new[185]	_	_
24-20	3827-3834	reduced	quantity[180]|abstract[185]	new[180]|new[185]	_	_
24-21	3835-3844	incidence	quantity[180]|abstract[185]	new[180]|new[185]	_	_
24-22	3845-3847	of	quantity[180]|abstract[185]	new[180]|new[185]	_	_
24-23	3848-3854	severe	quantity[180]|abstract[185]|abstract[188]	new[180]|new[185]|new[188]	_	_
24-24	3855-3867	drug-related	quantity[180]|abstract[185]|abstract[186]|abstract[188]	new[180]|new[185]|giv[186]|new[188]	_	_
24-25	3868-3871	AEs	quantity[180]|abstract[185]|abstract[186]|abstract[188]	new[180]|new[185]|giv[186]|new[188]	_	_
24-26	3872-3875	and	quantity[180]|abstract[185]|abstract[188]	new[180]|new[185]|new[188]	_	_
24-27	3876-3891	discontinuation	quantity[180]|abstract[185]|event|abstract[188]	new[180]|new[185]|giv|new[188]	_	_
24-28	3892-3899	therapy	quantity[180]|abstract[185]|abstract[188]	new[180]|new[185]|new[188]	_	_
24-29	3900-3901	.	_	_	_	_

#Text=In conclusion , when closely monitoring patients , the ability of clinicians to make rapid therapeutic decisions in the event of medical complications is critical in the diagnosis and management of TKI-related side effects .
25-1	3902-3904	In	_	_	_	_
25-2	3905-3915	conclusion	abstract	new	_	_
25-3	3916-3917	,	_	_	_	_
25-4	3918-3922	when	_	_	_	_
25-5	3923-3930	closely	_	_	_	_
25-6	3931-3941	monitoring	_	_	_	_
25-7	3942-3950	patients	person	giv	coref	28-23[228_0]
25-8	3951-3952	,	_	_	_	_
25-9	3953-3956	the	abstract[191]	new[191]	_	_
25-10	3957-3964	ability	abstract[191]	new[191]	_	_
25-11	3965-3967	of	abstract[191]	new[191]	_	_
25-12	3968-3978	clinicians	abstract[191]|person	new[191]|new	_	_
25-13	3979-3981	to	_	_	_	_
25-14	3982-3986	make	_	_	_	_
25-15	3987-3992	rapid	abstract[193]	new[193]	_	_
25-16	3993-4004	therapeutic	abstract[193]	new[193]	_	_
25-17	4005-4014	decisions	abstract[193]	new[193]	_	_
25-18	4015-4017	in	_	_	_	_
25-19	4018-4021	the	event[194]	giv[194]	_	_
25-20	4022-4027	event	event[194]	giv[194]	_	_
25-21	4028-4030	of	event[194]	giv[194]	_	_
25-22	4031-4038	medical	event[194]|abstract[195]	giv[194]|new[195]	coref	26-10[201_195]
25-23	4039-4052	complications	event[194]|abstract[195]	giv[194]|new[195]	_	_
25-24	4053-4055	is	_	_	_	_
25-25	4056-4064	critical	_	_	_	_
25-26	4065-4067	in	_	_	_	_
25-27	4068-4071	the	abstract[196]	new[196]	ana	26-1[0_196]
25-28	4072-4081	diagnosis	abstract[196]	new[196]	_	_
25-29	4082-4085	and	_	_	_	_
25-30	4086-4096	management	organization[197]	new[197]	_	_
25-31	4097-4099	of	organization[197]	new[197]	_	_
25-32	4100-4111	TKI-related	organization[197]|abstract[198]	new[197]|giv[198]	coref	27-18[212_198]
25-33	4112-4116	side	organization[197]|abstract[198]	new[197]|giv[198]	_	_
25-34	4117-4124	effects	organization[197]|abstract[198]	new[197]|giv[198]	_	_
25-35	4125-4126	.	_	_	_	_

#Text=This is even more decisive in the event of serious or even life-threatening complications .
26-1	4127-4131	This	abstract	giv	_	_
26-2	4132-4134	is	_	_	_	_
26-3	4135-4139	even	_	_	_	_
26-4	4140-4144	more	_	_	_	_
26-5	4145-4153	decisive	_	_	_	_
26-6	4154-4156	in	_	_	_	_
26-7	4157-4160	the	event[200]	giv[200]	_	_
26-8	4161-4166	event	event[200]	giv[200]	_	_
26-9	4167-4169	of	event[200]	giv[200]	_	_
26-10	4170-4177	serious	event[200]|abstract[201]	giv[200]|giv[201]	_	_
26-11	4178-4180	or	event[200]|abstract[201]	giv[200]|giv[201]	_	_
26-12	4181-4185	even	event[200]|abstract[201]	giv[200]|giv[201]	_	_
26-13	4186-4202	life-threatening	event[200]|abstract[201]	giv[200]|giv[201]	_	_
26-14	4203-4216	complications	event[200]|abstract[201]	giv[200]|giv[201]	_	_
26-15	4217-4218	.	_	_	_	_

#Text=However , good clinician – patient communication , drug patient education , early detection and management of drug side effects , and monitoring of disease response with plasma concentration quantification can also improve patient outcomes .
27-1	4219-4226	However	_	_	_	_
27-2	4227-4228	,	_	_	_	_
27-3	4229-4233	good	person[202]	giv[202]	_	_
27-4	4234-4243	clinician	person[202]	giv[202]	_	_
27-5	4244-4245	–	_	_	_	_
27-6	4246-4253	patient	person|abstract[204]	giv|new[204]	coref|coref	27-10|27-10
27-7	4254-4267	communication	abstract[204]	new[204]	_	_
27-8	4268-4269	,	_	_	_	_
27-9	4270-4274	drug	substance|abstract[207]	giv|giv[207]	coref|coref	27-18|27-18
27-10	4275-4282	patient	person|abstract[207]	giv|giv[207]	coref	27-34
27-11	4283-4292	education	abstract[207]	giv[207]	_	_
27-12	4293-4294	,	_	_	_	_
27-13	4295-4300	early	abstract[208]	new[208]	_	_
27-14	4301-4310	detection	abstract[208]	new[208]	_	_
27-15	4311-4314	and	_	_	_	_
27-16	4315-4325	management	organization[209]	new[209]	_	_
27-17	4326-4328	of	organization[209]	new[209]	_	_
27-18	4329-4333	drug	organization[209]|substance|abstract[212]	new[209]|giv|giv[212]	_	_
27-19	4334-4338	side	organization[209]|abstract|abstract[212]	new[209]|new|giv[212]	_	_
27-20	4339-4346	effects	organization[209]|abstract[212]	new[209]|giv[212]	_	_
27-21	4347-4348	,	_	_	_	_
27-22	4349-4352	and	_	_	_	_
27-23	4353-4363	monitoring	event[213]	new[213]	_	_
27-24	4364-4366	of	event[213]	new[213]	_	_
27-25	4367-4374	disease	event[213]|abstract|abstract[215]	new[213]|giv|giv[215]	_	_
27-26	4375-4383	response	event[213]|abstract[215]	new[213]|giv[215]	_	_
27-27	4384-4388	with	event[213]|abstract[215]	new[213]|giv[215]	_	_
27-28	4389-4395	plasma	event[213]|abstract[215]|abstract|abstract[218]	new[213]|giv[215]|new|new[218]	_	_
27-29	4396-4409	concentration	event[213]|abstract[215]|abstract|abstract[218]	new[213]|giv[215]|new|new[218]	_	_
27-30	4410-4424	quantification	event[213]|abstract[215]|abstract[218]	new[213]|giv[215]|new[218]	_	_
27-31	4425-4428	can	_	_	_	_
27-32	4429-4433	also	_	_	_	_
27-33	4434-4441	improve	_	_	_	_
27-34	4442-4449	patient	person|abstract[220]	giv|new[220]	_	_
27-35	4450-4458	outcomes	abstract[220]	new[220]	_	_
27-36	4459-4460	.	_	_	_	_

#Text=Close cooperation between oncologists , internists , pharmaceutics , and nurses should become the gold standard in the comprehensive clinical care of advanced NSCLC patients receiving TKIs .
28-1	4461-4466	Close	abstract[221]	new[221]	_	_
28-2	4467-4478	cooperation	abstract[221]	new[221]	_	_
28-3	4479-4486	between	abstract[221]	new[221]	_	_
28-4	4487-4498	oncologists	abstract[221]|person[222]	new[221]|giv[222]	_	_
28-5	4499-4500	,	abstract[221]|person[222]	new[221]|giv[222]	_	_
28-6	4501-4511	internists	abstract[221]|person[222]|person	new[221]|giv[222]|new	_	_
28-7	4512-4513	,	abstract[221]|person[222]	new[221]|giv[222]	_	_
28-8	4514-4527	pharmaceutics	abstract[221]|person[222]|person	new[221]|giv[222]|new	_	_
28-9	4528-4529	,	abstract[221]|person[222]	new[221]|giv[222]	_	_
28-10	4530-4533	and	abstract[221]|person[222]	new[221]|giv[222]	_	_
28-11	4534-4540	nurses	abstract[221]|person[222]|person	new[221]|giv[222]|giv	_	_
28-12	4541-4547	should	_	_	_	_
28-13	4548-4554	become	_	_	_	_
28-14	4555-4558	the	_	_	_	_
28-15	4559-4563	gold	_	_	_	_
28-16	4564-4572	standard	_	_	_	_
28-17	4573-4575	in	_	_	_	_
28-18	4576-4579	the	abstract[226]	giv[226]	_	_
28-19	4580-4593	comprehensive	abstract[226]	giv[226]	_	_
28-20	4594-4602	clinical	abstract[226]	giv[226]	_	_
28-21	4603-4607	care	abstract[226]	giv[226]	_	_
28-22	4608-4610	of	abstract[226]	giv[226]	_	_
28-23	4611-4619	advanced	abstract[226]|person[228]	giv[226]|giv[228]	_	_
28-24	4620-4625	NSCLC	abstract[226]|abstract|person[228]	giv[226]|giv|giv[228]	_	_
28-25	4626-4634	patients	abstract[226]|person[228]	giv[226]|giv[228]	_	_
28-26	4635-4644	receiving	_	_	_	_
28-27	4645-4649	TKIs	event	new	_	_
28-28	4650-4651	.	_	_	_	_
